| Full text | |
| Author(s): |
Zuglianello, Carine
;
Lemos-Senna, Elenara
Total Authors: 2
|
| Document type: | Journal article |
| Source: | Journal of Microencapsulation; v. 39, n. 2, p. 20-pg., 2022-03-29. |
| Abstract | |
This review gathers recent studies, patents, and clinical trials involving the nasal administration of peptide drugs to supply a panorama of developing nanomedicine advances in this field. Peptide drugs have been featured in the pharmaceutical market, due to their high efficacy, biological activity, and low immunogenicity. Pharmaceutical industries need technology to circumvent issues relating to peptide stability and bioavailability. The oral route offers very harsh and unfavourable conditions for peptide administration, while the parenteral route is inconvenient and risky for patients. Nasal administration is an attractive alternative, mainly when associated with nanotechnological approaches. Nanomedicines may improve the nasal administration of peptide drugs by providing protection for the macromolecules from enzymes while also increasing their time of retention and permeability in the nasal mucosa. Nanomedicines for nasal administration containing peptide drugs have been acclaimed for both prevention, and treatment, of infections, including the pandemic COVID-19, cancers, metabolic and neurodegenerative diseases. (AU) | |
| FAPESP's process: | 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach |
| Grantee: | Maria Vitória Lopes Badra Bentley |
| Support Opportunities: | Research Projects - Thematic Grants |